Skip to main content

Table 5 Correlation of molecular biomarker expression and chemotherapeutic response

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Molecular biomarkers HGSC CCC
  Platinum sensitive (%) aPlatinum resistant (%) HGSCP Platinum sensitive (%) aPlatinum resistant (%) CCC P
EGFR    0.365    0.129
 Negative 58(75.3) 20(66.7)   36(58.1) 17(77.3)  
 Positive 19(24.7) 10(33.3)   26(41.9) 5(22.7)  
HER2    1.000    0.725
 Negative 75(97.4) 29(96.7)   56(87.5) 19(82.6)  
 Positive 2(2.6) 1(3.3)   8(12.5) 4(17.4)  
PTEN    0.530    0.679
 Negative 68(88.3) 25(83.3)   58(92.1) 21(87.5)  
 Positive 9(11.7) 5(16.7)   5(7.9) 3(12.5)  
AURKA    0.505    0.042
 Negative 49(63.6) 17(56.7)   42(65.6) 10(41.7)  
 Positive 28(36.3) 13(43.3)   22(34.4) 14(58.3)  
BRCA1    0.584    0.848
 Negative 55(71.4) 23(76.7)   35(56.5) 13(54.2)  
 Positive 22(28.6) 7(23.3)   27(43.5) 11(45.8)  
BRCA2    1.000    0.542
 Negative 68(88.3) 27(90.0)   50(80.6) 21(87.5)  
 Positive 9(11.7) 3(10.0)   12(19.4) 3(12.5)  
PD-L1    0.502    0.028
 Negative 66(86.8) 28(93.3)   56(87.5) 15(65.2)  
 Positive 10(13.2) 2(6.7)   8(12.5) 8(34.8)  
  1. There are 107 cases of HGSC and 88 cases of CCC having both primary tumor immunohistochemistry results and information of chemotherapy. However, the total number for each antibody does not add to up 107 and 88, respectively
  2. aInterval time <6 months from completion of last platinum-based chemotherapy to disease recurrence
  3. Bold value denotes P with statistical significance